Abiomed shells out $100,000 to lobby feds

It's always good to have friends in high places in Washington. And in the nation's capitol, you can always buy new ones.

In another indication of just how important the Medicare market is for biopharma companies, Abiomed revealed that it had paid the influential lobbying group Barbour Griffith & Rogers $100,000 in the first half of this year to lobby Congress and HHS on issues related to Medicare reimbursement and regulatory approval.

- read the Boston Globe report

ALSO: Coincidentally, Abiomed also announced that the FDA has OK'd a new study of a system designed to provide blood flow to patients undergoing surgery. Release

Related Articles:
Amgen ups lobbying efforts. Report
Biomedical researchers lobby against funding cuts. Report
Bay area biotechs plan new lobbying strategy. Report
Crawford signs on as Washington lobbyist. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.